Abiraterone acetate plus prednisone and ADT is associated with improved health-related quality of life compared with ADT plus placebo among patients with metastatic castration-naïve prostate cancer.

Research in Review

A retrospective analysis of hospital trends has shown that the likelihood of receiving expectant management for low-risk prostate cancer was significantly lower in men evaluated at community centers compared with academic centers.

Read More

Findings from a study recently published in the New England Journal of Medicine suggest that men with advanced prostate cancer may want to consider being tested for inherited gene mutations in order to help guide treatment decision-making and alert family members who may be at risk for a range of cancers.

Read More

A recent study showed a 98.6% cure rate at 5 years with stereotactic body radiation therapy (SBRT) in patients with low- or intermediate-risk prostate cancer.

Read More

A percentage of patients on active surveillance for clinically insignificant prostate cancer may be at risk of developing metastatic disease in the long term. A study published in The Journal of Urology has reported the clinical and pathological factors that correlate with risk of metastasis in this patient population.

Read More

Subscribe to Prostate Cancer